New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
08:04 EDTNAVBNavidea completes study of radiopharmaceutical NAV4694
Navidea Biopharmaceuticals announced the completion of a study of its novel radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral b-amyloid in diagnosing Alzheimer's disease, or AD. The study was designed and conducted by Navidea's partner, AstraZeneca, to assess the effects of various mass amounts of AZD4694, or NAV4694, on safety and the efficacy of Positron Emission Tomography scanning in subjects with AD and in healthy volunteers. Evaluations were completed on the effects of two mass doses of the radioligand on binding parameters and overall image quality. These endpoints are typical and important requirements of drug registration dossiers filed with regulatory authorities for approval of diagnostic agents.
News For NAVB From The Last 14 Days
Check below for free stories on NAVB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 7, 2014
07:20 EDTNAVBNavidea price target raised to $5 from $3 at JMP Securities
JMP Securities increased its price target on Navidea after the company reported higher than expected Q2 Lymphoseek sales and operating income. The firm thinks the company has a number of significant growth drivers and keeps an Outperform rating on the shares.
August 6, 2014
07:33 EDTNAVBNavidea still sees FY Lymphoseek revenue of $5M-$6M
Subscribe for More Information
07:32 EDTNAVBNavidea reports Q2 EPS (7c), consensus (7c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use